Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

• Status: Completed
• Trial end date: 2019-01-24
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

• Healthy male between 19 and 50 years of age at the time of screening

• Weight between 50 kg and 90 kg and body mass index (BMI) between 18.0 kg/m2 and 27.0 kg/m2

Exclusion Criteria:

• Clinically significant disease or history of clinically significant disease such as liver, kidney, nervous system, respiratory, endocrine*hematologic, cardiovascular, urinary, psychiatric

• Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery

• HDL values less than 35 mg/dL

• AST, ALT values over than 1.5 times of ULN at screening

• A person who has a history of drug abuse or who has positive result for an abuse drug in a urine screening test